Today's pre-market stock movers: NFLX, NVAX, ASML, BBWI and more

• $Omnicom Group (OMC.US)$ +6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58)

• $Fulton Financial (FULT.US)$ +4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c)

• $Abbott Laboratories (ABT.US)$ +0.6% (Abbott Laboratories raised its full-year earnings guidance after posting a wider profit and 10% sales jump for the second quarter.)

• $Nasdaq (NDAQ.US)$ +0.5% (Nasdaq Q2 earnings beat with Solutions Segment revenue climbing 10% Y/Y)

• $Aehr Test Systems (AEHR.US)$ +7.3% (receives $12.8 mln in orders from its lead silicon carbide test and burn-in customer)

• $Biodesix (BDSX.US)$ +4.5% (to present data at IASLC 2022 World Conference demonstrating that the VeriStrat Test is predictive of progression free survival and overall survival in patients with low or negative PD-L1 treated with immune checkpoint inhibitors)

• $Belite Bio (BLTE.US)$ +3.4% (submits IND application to FDA for LBS-008 Phase 3 clinical trial)

• $Roku Inc (ROKU.US)$ +2%, $Disney (DIS.US)$ +1.5% (in sympathy with NFLX earnings)

• $Lattice Semiconductor (LSCC.US)$ +1.5% (collaborates with LG to bring edge AI technology to LG's 2022 premium laptop lineup)

• $Forestar Group (FOR.US)$ -10% (Forestar Group shares dived after lot deliveries slid in the third quarter and the company cut its guidance for fiscal 2022)

• $Baker Hughes (BKR.US)$ -4.7% (Baker Hughes missed estimated earnings by 50.0%, reporting an EPS of $0.11 versus an estimate of $0.22)

• $Biogen (BIIB.US)$ -1% (Biogen said it expects earnings to be somewhere between $15.25 to $16.75 per share for this year, more than its prior expectation of $14.25 to $16.00 a share)

• $ASML Holding (ASML.US)$ -0.9% (ASML 2Q Net Profit Rose, Lowers 2022 Revenue Guidance on Delays)

• $Vascular Biogenics (VBLT.US)$ -77.1% (announces top-line data from OVAL Trial)

• $Revolution Medicines (RVMD.US)$ -11.5% (prices offering of 11.5 mln shares of common stock at $20.00 per share)

• $Inozyme Pharma (INZY.US)$ -4.8% (announces preliminary data from Phase 1/2 trial of INZ-701)

• $Singular Genomics (OMIC.US)$ -3.4% (files for $250 mln mixed securities shelf offering)

• $Golden Ocean (GOGL.US)$ -3% (files mixed securities shelf offering)

• $Merck & Co (MRK.US)$ -0.9% (reports Phase 3 KEYNOTE-412 Trial did not meet its primary endpoint)

• $Atara Biotherapeutics (ATRA.US)$ -4.4% (downgraded to Sell from Neutral at Citigroup)

• $Arista Networks (ANET.US)$ -3.9% (downgraded to Underperform from Buy at BofA Securities)